Guest guest Posted June 11, 2008 Report Share Posted June 11, 2008 Pediatric and heritable disorders: Use of tumor necrosis factor inhibitors in uveitis www.co-rheumatology.com/pt/re/corheum/abstract.00002281-200709000-00015.htm Current Opinion in Rheumatology. 19(5):482-486, September 2007. Rabinovich, C Egla Abstract: Purpose of review: Use of tumor necrosis factor-[alpha] blocking agents to treat chronic pediatric uveitis is becoming recognized as an important therapeutic modality. This review summarizes the rationale for this use, highlighting new studies of these agents in pediatric uveitis. Recent findings: The majority of patients with pediatric uveitis either have idiopathic uveitis or uveitis associated with juvenile idiopathic arthritis. Ophthalmologic morbidity among these children is common. Most studies evaluating tumor necrosis factor-[alpha] blockade in pediatric uveitis are retrospective case series, with attendant limitations that are inherent to any retrospective study. Study of uveitis has been hampered by lack of standardization of disease and outcome measures, which has been addressed by uveitis experts with publication of consensus measures. Data to date suggest that tumor necrosis factor-[alpha] blockade is efficacious in refractory uveitis. Agents with direct tumor necrosis factor-[alpha] membrane receptor binding activity may be the most efficacious. There remain many unanswered questions in the treatment of pediatric uveitis, including optimal dosing regimen and long-term efficacy. Summary: Tumor necrosis factor-[alpha] blocking agents play an important role in the treatment of chronic pediatric uveitis. Prospective comparative studies are needed so that we may better understand this role. © 2007 Lippincott & Wilkins, Inc. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.